DarioHealth (NASDAQ:DRIO) Price Target Lowered to $8.00 at TD Cowen

Key Points

• TD Cowen lowered DarioHealth’s price target to $8 from $11 and maintained a “hold” rating, implying roughly 3.8% upside from the $7.71 share price. Analysts’ overall consensus remains “Hold,” with an average target of $9.
• DarioHealth’s latest quarter showed a narrower-than-expected loss and improving margins, but revenue of $5.18 million fell short of the $5.92 million consensus estimate. The company remains deeply unprofitable, with analysts forecasting a full-year loss of $3.12 per share.
• The company reported more than $13.1 million in contracted and late-stage annual recurring revenue and $36.8 million in pro forma cash after a $22.8 million July financing, though the equity raise may dilute existing shareholders.

DarioHealth (NASDAQ:DRIO - Get Free Report) had its price objective decreased by research analysts at TD Cowen from $11.00 to $8.00 in a research note issued on Wednesday,Benzinga reports. The firm currently has a "hold" rating on the stock. TD Cowen's price target indicates a potential upside of 3.76% from the stock's current price.

Other equities analysts have also issued reports about the company. Stifel Nicolaus reaffirmed a "buy" rating and issued a $10.00 price objective on shares of DarioHealth in a research note on Thursday, May 14th. Weiss Ratings restated a "sell (e+)" rating on shares of DarioHealth in a report on Friday, July 10th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $9.00.

DarioHealth Trading Up 0.5%

NASDAQ DRIO traded up $0.04 on Wednesday, reaching $7.71. The company had a trading volume of 7,123 shares, compared to its average volume of 15,280. The firm has a market cap of $56.59 million, a price-to-earnings ratio of -0.87 and a beta of 1.11. DarioHealth has a fifty-two week low of $5.84 and a fifty-two week high of $17.74. The business has a 50 day moving average of $7.10 and a two-hundred day moving average of $8.30. The company has a debt-to-equity ratio of 0.50, a current ratio of 3.07 and a quick ratio of 2.62.

DarioHealth (NASDAQ:DRIO - Get Free Report) last announced its earnings results on Tuesday, August 11th. The company reported ($0.85) EPS for the quarter, topping the consensus estimate of ($1.22) by $0.37. The firm had revenue of $5.18 million for the quarter, compared to the consensus estimate of $5.92 million. DarioHealth had a negative return on equity of 60.52% and a negative net margin of 192.23%. Analysts forecast that DarioHealth will post -3.12 EPS for the current year.

Insider Buying and Selling

In other DarioHealth news, Director Dennis Matheis bought 14,430 shares of the firm's stock in a transaction that occurred on Thursday, July 23rd. The stock was acquired at an average price of $6.93 per share, with a total value of $99,999.90. Following the completion of the purchase, the director directly owned 43,026 shares of the company's stock, valued at approximately $298,170.18. This trade represents a 50.46% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link. 3.50% of the stock is owned by corporate insiders.

Institutional Trading of DarioHealth

Several hedge funds have recently modified their holdings of DRIO. XTX Topco Ltd boosted its holdings in DarioHealth by 229.0% in the second quarter. XTX Topco Ltd now owns 62,511 shares of the company's stock worth $42,000 after acquiring an additional 43,513 shares in the last quarter. Geode Capital Management LLC increased its stake in DarioHealth by 167.9% during the 4th quarter. Geode Capital Management LLC now owns 49,567 shares of the company's stock valued at $564,000 after purchasing an additional 31,063 shares in the last quarter. Kestra Advisory Services LLC bought a new stake in DarioHealth during the 4th quarter valued at $35,000. Finally, BlackRock Inc. acquired a new position in DarioHealth during the second quarter worth $249,000. Institutional investors own 33.39% of the company's stock.

Trending Headlines about DarioHealth

Here are the key news stories impacting DarioHealth this week:

• Positive Sentiment: Revenue totaled approximately $5.2 million, while the quarterly loss per share was narrower than analysts expected. The company also reduced its operating loss by 30% year over year and operating expenses by 21%, indicating improving cost discipline. DarioHealth Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Gross margin improved to 62% from 57% in the prior quarter and 55% a year earlier. Dario said its B2B2C gross margin remained approximately 80% for the 10th consecutive quarter, supporting the profitability potential of its business model. DarioHealth Q2 2026 Earnings Highlights
• Positive Sentiment: Management highlighted more than $13.1 million of contracted and late-stage annual recurring revenue, with over 80% tied to its multi-condition platform. Recent wins include an expansion with a top-five national health plan, a Fortune 50 customer and a new health insurer through Amwell; the largest expansion could nearly triple Dario’s potential revenue opportunity with that client. DarioHealth Q2 2026 Earnings Call Transcript
• Positive Sentiment: Dario reported pro forma cash of $36.8 million after raising $22.8 million in July, providing additional funding for product development and commercial expansion.
• Neutral Sentiment: The company expanded into provider-backed clinical care delivery, which could increase revenue per customer but also broadens its execution requirements. A comparison article with Ascom provides industry perspective but does not identify a specific new catalyst for DRIO. Critical Survey: DarioHealth versus Ascom
• Negative Sentiment: Quarterly revenue came in below the roughly $5.9 million consensus estimate, and Dario remains deeply unprofitable. The company’s decision to discontinue certain pharmaceutical-related business also reduced reported revenue, creating a near-term headwind despite the stated focus on higher-quality growth. DarioHealth Reports Q2 Loss and Lags Revenue Estimates
• Negative Sentiment: The July equity financing strengthened liquidity but may dilute existing shareholders. Trading was also temporarily halted under a volatility-based LULD pause, signaling elevated short-term trading risk.

DarioHealth Company Profile

DarioHealth NASDAQ: DRIO is a digital health company specializing in chronic disease management through a smartphone-based care platform. Its core solution combines connected devices—such as glucose meters, blood pressure monitors and smart scales—with real-time data analytics and personalized coaching. The platform is designed to support individuals living with diabetes, hypertension, weight management challenges and other cardiometabolic conditions, offering continuous monitoring, tailored insights and behavioral nudges aimed at improving clinical outcomes.

The Dario platform integrates artificial intelligence and machine learning to deliver personalized guidance and education.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source